An investment bank like no other
Deep capital markets expertise paired with fundamental science.
Brookline blends comprehensive life sciences knowledge with robust capital markets capabilities. Brookline is also a pioneer in growth industries like defense, technology, and SPACs.
- 70%Repeat business
- 300+Engagements completed to date
- $35B+Value of all transactions
- $1.5B+Private-to-public value creation
- 30+SPACs completed
What we do
A full-service platform for cutting-edge life sciences, med. tech. and diagnostics companies, as well as for other emerging growth enterprises and SPACs.
Capital Markets
Private placements, IPOs, follow-ons, confidentially marketed public offerings, registered directs, PIPEs, and converts.
Mergers & Acquisitions
Sell-side and buy-side advisory.
Strategic Financial Advisory
Recapitalizations, capital-structure counsel and strategic transitions for companies at every stage of clinical and financial maturity.
Equity Research
Institutional-grade coverage across life sciences, med. tech. and diagnostics from a recognized research team.
Corporate Access
Connecting companies and investors through fireside chats, non-deal roadshows, KOL events and other events.
Sales & Trading
Strong relationships with a curated network of healthcare-focused institutional, ultra-high-net-worth, and family office investors, as well as with other growth and SPAC investors.
Global sourcing
The Brookline Client Network
Brookline is recognized for its differentiated ability to source capital from traditional institutional investors, as well as from its proprietary network of global family offices and ultra-high-net-worth investors. Our greatest source of pride is the success and longevity of our clients as they grow and flourish.
Featured Transactions
All Transactions- April 2025
Alcyone TherapeuticsBrookline served as Exclusive Placement Agent for the Series F Convertible Preferred stock offering. - September 2025
Sale to BiogenBiogen acquired Alcyone Therapeutics in 2025. Brookline served as Alcyone's financial advisor. - July 2026
Neela TherapeuticsNeela Therapeutics was spun out of the acquisition and Brookline served as the Exclusive Placement Agent for a Convertible Note in 2026.
The Brookline Brief
All issuesPublication
The Brookline Brief, November 2026
Our monthly publication of the Brookline Brief, discussing the current state of the life sciences, med. tech., and diagnostics subsegments of the Equity Capital Markets.
Read the Latest BriefSPAC & Forth
All issuesNewsletter
The Butterfly Effect in SPACs. A Perfect Storm?
Authored by Brookline's Dimitre Genov and read by more than 12,000 SPAC investors, sponsors and issuers.
Read SPAC & ForthLatest News
All News- Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
- Ocean Capital Acquisition Corporation Prices $100 Million Initial Public Offering
- Aeon Acquisition I Corp. Announces Pricing of $125 Million Initial Public Offering
- Perimeter Medical Imaging AI Closes Life Offering
- ZeroToOne.AI Acquires GroundTruth to Deploy at Scale an AI Driven Predictive Intelligence Platform for Enterprise Decision Systems
- Candel Therapeutics Announces Proposed $100 Million Public Offering
Let’s Work Together
Our team is built to be your long-term capital markets partner.